Roundtable: 3 Stocks Preparing to Shock the Market

Stocks we're watching to surprise on earnings

Jul 19, 2014 at 5:16PM

Earnings season is upon us, so we decided to ask our top health care contributors to identify the stock they're watching to surprise on earnings. Here are the companies they singled out.

George BudwellNext week, I expect Cubist Pharmaceuticals (NASDAQ:CBST) to surprise to the upside.

Cubist is set to report second-quarter earnings on July 22 after the bell. The Street is expecting earnings per share of $0.02 on $299.6 million in revenue for the quarter. Consensus has nonetheless fallen dramatically over the course of the quarter for two reasons.

Firstly, Cubist is gearing up to launch Sivextro, indicated for acute bacterial skin and skin structure infections, thus increasing operational costs. More importantly, the Street lost faith in Cubicin's growth story after the drug posted weak sales numbers in the first-quarter of 2014.

And that's where I think the Street will get caught flat-footed this quarter. Cubist's management decided to maintain its full year guidance of $1.19 to $1.275 billion following its first-quarter hiccup, whereas many analysts lowered their projections to around a billion.

What's important to understand is that Cubicin's growth is supposed to be uneven due to seasonality in the marketplace. Put simply, I think revenues will come in closer to $310 million for the second quarter based on a seasonal upswing in Cubicin sales.

Todd CampbellDespite shares hitting new highs, I like Molina Healthcare (NYSE:MOH) heading into earnings.

Although just 26 states (plus DC) are embracing Medicaid expansion, the Centers for Medicare and Medicaid report that six million people have signed up for Medicaid coverage following the ACA's launch last fall. That brought total Medicaid enrollment to 65 million people at the end of April, up 10% from last October.

Surging enrollment is good news for insurers administering state programs, but it's particularly good news for specialty insurers like Molina given that the vast majority of Molina's revenue is tied to Medicaid. Molina's sales jumped 21% in the first quarter thanks in part to 47,000 new Medicaid members in California.

A big backlog of Medicaid applicants in California (several hundred thousand applications still need to be processed as of last week) continues to provide a tailwind, but Michigan should help Molina's quarter too. Molina served 218,000 Medicaid members in Michigan exiting Q1, but that number should jump given that Michigan reported signing up 323,000 new Medicaid members over the past 14 weeks. 

Brian Orelli: Sales for Gilead Sciences' (NASDAQ:GILD) Sovaldi aren't likely to be much of a surprise. We already know they're going to be huge.

First quarter sales were nearly $2.3 billion, and prescription data for the hepatitis C drug suggests that sales should be higher in the second quarter since prescriptions continued to climb until the beginning of May before flattening out. It's hard to know exactly how much higher because discounts aren't known and prescription data isn't 100% accurate, but a $3-billion quarter isn't out of the question according to ISI analyst Mark Schoenebaum.

The surprise could come in what Gilead says about the potential for sales in the current quarter. With an all-oral combination of Sovaldi and Gilead's ledipasvir potentially being approved in October, doctors may warehouse patients, waiting for the easier-to-take cocktail.

While warehousing would delay payment, it would ultimately be good news for Gilead because many of the patients are currently being treated with a combination of Sovaldi and Johnson & Johnson's Olysio. If patients delay treatment, Gilead can capture the full sales value for those patients, assuming Sovaldi-ledipasvir costs more than Sovaldi alone.

Leaked: A huge market-shocking opportunity
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

The Motley Fool recommends Cubist Pharmaceuticals, Gilead Sciences, and Johnson & Johnson. The Motley Fool owns shares of Cubist Pharmaceuticals, Gilead Sciences, and Johnson & Johnson. Todd Campbell owns shares of Gilead and Molina. George Budwell owns shares of Gilead. Brian Orelli has no positions in any stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers